Literature DB >> 10364115

Oral contraceptives and myocardial infarction: results of the MICA case-control study.

N Dunn1, M Thorogood, B Faragher, L de Caestecker, T M MacDonald, C McCollum, S Thomas, R Mann.   

Abstract

OBJECTIVES: To determine the association between myocardial infarction and use of different types of oral contraception in young women.
DESIGN: Community based case-control study. Data from interviews and general practice records.
SETTING: England, Scotland, and Wales. PARTICIPANTS: Cases (n=448) were recruited from women aged between 16 and 44 who had suffered an incident myocardial infarction between 1 October 1993 and 16 October 1995. Controls (n=1728) were women without a diagnosis of myocardial infarction matched for age and general practice. MAIN OUTCOME MEASURES: Odds ratios for myocardial infarction in current users of all combined oral contraceptives stratified by their progestagen content compared with non-users; current users of third generation versus second generation oral contraceptives.
RESULTS: The adjusted odds ratio for myocardial infarction was 1.40 (95% confidence interval 0.78 to 2. 52) for all combined oral contraceptive users, 1.10 (0.52 to 2.30) for second generation users, and 1.96 (0.87 to 4.39) for third generation users. Subgroup analysis by progestagen content did not show any significant difference from 1, and there was no effect of duration of use. The adjusted odds ratio for third generation users versus second generation users was 1.78 (0.66 to 4.83). 87% of cases were not exposed to an oral contraceptive, and 88% had clinical cardiovascular risk factors or were smokers, or both. Smoking was strongly associated with myocardial infarction: adjusted odds ratio 12.5 (7.29 to 21.5) for smoking 20 or more cigarettes a day.
CONCLUSIONS: There was no significant association between the use of oral contraceptives and myocardial infarction. The modest and non-significant point estimates for this association have wide confidence intervals. There was no significant difference between second and third generation products.

Entities:  

Keywords:  Behavior; Biology; Case Control Studies; Contraception; Contraceptive Methods--side effects; Developed Countries; Diseases; England; Europe; Family Planning; Heart Diseases; Myocardial Infarction--women; Northern Europe; Oral Contraceptives, Combined--side effects; Oral Contraceptives--side effects; Research Methodology; Research Report; Risk Factors--women; Scotland; Smoking--women; Studies; United Kingdom; Wales; Women

Mesh:

Substances:

Year:  1999        PMID: 10364115      PMCID: PMC28136          DOI: 10.1136/bmj.318.7198.1579

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  11 in total

1.  Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

2.  The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.

Authors:  M A Lewis; L A Heinemann; W O Spitzer; K D MacRae; R Bruppacher
Journal:  Contraception       Date:  1997-09       Impact factor: 3.375

3.  Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study.

Authors:  H Tunstall-Pedoe; M Woodward; R Tavendale; R A'Brook; M K McCluskey
Journal:  BMJ       Date:  1997-09-20

4.  Oral contraceptive use and the risk of myocardial infarction.

Authors:  L Rosenberg; J R Palmer; S M Lesko; S Shapiro
Journal:  Am J Epidemiol       Date:  1990-06       Impact factor: 4.897

Review 5.  The primary prevention of coronary heart disease in women.

Authors:  J W Rich-Edwards; J E Manson; C H Hennekens; J E Buring
Journal:  N Engl J Med       Date:  1995-06-29       Impact factor: 91.245

6.  Myocardial infarction in users of low-dose oral contraceptives.

Authors:  S Sidney; D B Petitti; C P Quesenberry; A L Klatsky; H K Ziel; S Wolf
Journal:  Obstet Gynecol       Date:  1996-12       Impact factor: 7.661

7.  Myocardial infarction and oral contraceptives, a retrospective case control study in England and Scotland ('MICA' Study).

Authors:  N R Dunn; M Thorogood; L de Caestecker; R D Mann
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-07       Impact factor: 2.890

8.  A study to determine the sensitivity and specificity of hospital discharge diagnosis data used in the MICA study.

Authors:  R McAlpine; S Pringle; T Pringle; R Lorimer; T M MacDonald
Journal:  Pharmacoepidemiol Drug Saf       Date:  1998-09       Impact factor: 2.890

9.  Risk factors for myocardial infarction in young women.

Authors:  C La Vecchia; S Franceschi; A Decarli; S Pampallona; G Tognoni
Journal:  Am J Epidemiol       Date:  1987-05       Impact factor: 4.897

10.  A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception.

Authors: 
Journal:  J Clin Epidemiol       Date:  1995-12       Impact factor: 6.437

View more
  19 in total

1.  The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills.

Authors:  P A O'Brien
Journal:  BMJ       Date:  1999-09-25

2.  Study confirms tendency towards lower risk of myocardial infarction with second generation oral contraceptives in UK.

Authors:  P O'Brien
Journal:  BMJ       Date:  1999-10-30

3.  The third generation pill controversy ("continued").

Authors:  J O Drife
Journal:  BMJ       Date:  2001-07-21

4.  Oral contraceptives and myocardial infarction.

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

Review 5.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

6.  Regional variation in incidence and case fatality of myocardial infarction among young women in England, Scotland and Wales.

Authors:  N R Dunn; A Arscott; M Thorogood; B Faragher; L de Caestecker; T M MacDonald; C McCollum; S Thomas; R D Mann
Journal:  J Epidemiol Community Health       Date:  2000-04       Impact factor: 3.710

Review 7.  Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?

Authors:  James Drife
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Contraceptive hormone use and cardiovascular disease.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

Review 9.  Risk of cardiovascular events with hormonal contraception: insights from the Danish cohort study.

Authors:  Omosalewa O Lalude
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 10.  Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  E Carmina
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.